Semaglutide vs. Dulaglutide for Heart Protection: Which GLP-1 Drug Wins?
In a study of over 75,000 people with diabetes and heart disease, semaglutide reduced the risk of heart attacks, strokes, and cardiovascular death by 22% compared to dulaglutide.
Quick Facts
What This Study Found
Among 75,243 U.S. adults with type 2 diabetes and established atherosclerotic cardiovascular disease, semaglutide users had a 22% lower risk of major adverse cardiovascular events (MACE) compared to dulaglutide users (HR 0.78, 95% CI 0.70–0.87, p<0.001).
MACE incidence rates were 25.7 per 1,000 person-years for semaglutide versus 33.0 for dulaglutide. After entropy balancing to account for baseline differences, all standardized mean differences were below 0.1, indicating well-matched cohorts.
Key Numbers
n=75,243 · HR 0.78 (95% CI 0.70–0.87) · p<0.001 · semaglutide MACE rate 25.7/1000 PY · dulaglutide MACE rate 33.0/1000 PY · 22% risk reduction
How They Did This
Retrospective cohort study using Optum's de-identified Clinformatics Data Mart (Medicare claims data) from January 2007 through September 2024. Included new initiators of semaglutide (n=42,007) or dulaglutide (n=33,236) aged 18+ with both type 2 diabetes and established atherosclerotic cardiovascular disease. Entropy balancing was used to match cohorts on baseline characteristics. Primary outcome was 3-point MACE (stroke, MI, CV death), analyzed with doubly robust Cox proportional hazard models.
Why This Research Matters
While both semaglutide and dulaglutide are GLP-1 receptor agonists approved for type 2 diabetes, clinicians have lacked direct head-to-head cardiovascular outcome data comparing them. This large real-world study fills that gap, suggesting semaglutide offers meaningfully better heart protection in patients who already have cardiovascular disease — a finding that could influence prescribing decisions for millions of high-risk patients.
The Bigger Picture
GLP-1 receptor agonists have gone from diabetes drugs to cardiovascular protectors, but they're not all equal. This study provides the strongest real-world evidence yet that semaglutide offers superior heart protection compared to dulaglutide, which could shift prescribing patterns and insurance formulary decisions for the millions of patients with both diabetes and heart disease.
What This Study Doesn't Tell Us
As a retrospective claims-based study, it cannot establish causation and may be subject to residual confounding despite entropy balancing. Medicare claims data may not capture all cardiovascular events or deaths. The study cannot determine which specific dose of each drug patients received, and adherence patterns are unknown. It reflects a U.S. Medicare population, which may not generalize to younger or international populations.
Questions This Raises
- ?Is semaglutide's cardiovascular advantage due to greater weight loss, direct vascular effects, or both?
- ?Would the same advantage hold for patients without established cardiovascular disease?
- ?How does tirzepatide's cardiovascular profile compare to semaglutide in this high-risk population?
Trust & Context
- Key Stat:
- 22% lower risk of MACE Semaglutide users had significantly fewer heart attacks, strokes, and cardiovascular deaths than dulaglutide users in this 75,000-person study
- Evidence Grade:
- Rated high because this is a large retrospective cohort study (n=75,243) with robust statistical methods including entropy balancing and doubly robust Cox models, though it falls short of a randomized controlled trial.
- Study Age:
- Published in 2026 with data through September 2024, this is among the most current real-world cardiovascular outcome comparisons between these two GLP-1 drugs.
- Original Title:
- Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.
- Published In:
- Diabetes, obesity & metabolism (2026)
- Authors:
- Tan, Xi(3), Liang, Yuanjie(2), Xie, Lin(5), Harton, Joanna, Gutierrez, Cynthia, Muhammad, Chalak, Swift, Caroline, de Havenon, Adam
- Database ID:
- RPEP-16219
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Does this mean semaglutide is better than dulaglutide for everyone with diabetes?
This study specifically looked at patients who already had heart disease. The 22% cardiovascular advantage may be most relevant for this high-risk group. For patients without heart disease, other factors like cost, insurance coverage, and side effect tolerance may matter more.
What is MACE and why does it matter?
MACE stands for Major Adverse Cardiovascular Events — specifically heart attack, stroke, and death from cardiovascular causes. It's the standard measure used to evaluate whether a drug protects or harms the heart, and is required by the FDA for diabetes drug approvals.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-16219APA
Tan, Xi; Liang, Yuanjie; Xie, Lin; Harton, Joanna; Gutierrez, Cynthia; Muhammad, Chalak; Swift, Caroline; de Havenon, Adam. (2026). Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70440
MLA
Tan, Xi, et al. "Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.." Diabetes, 2026. https://doi.org/10.1111/dom.70440
RethinkPeptides
RethinkPeptides Research Database. "Comparison of cardiovascular outcomes between once-weekly se..." RPEP-16219. Retrieved from https://rethinkpeptides.com/research/tan-2026-comparison-of-cardiovascular-outcomes
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.